Entero Therapeutics, Inc.
ENTO
$0.3541
-$0.0241-6.37%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 14.73M | 16.34M | 17.07M | 16.70M | 10.74M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 15.75M | 18.64M | 20.18M | 20.93M | 15.77M |
| Operating Income | -15.75M | -18.64M | -20.18M | -20.93M | -15.77M |
| Income Before Tax | -15.81M | -18.72M | -20.26M | -21.02M | -15.80M |
| Income Tax Expenses | -10.60M | -10.60M | -10.60M | -14.86M | -- |
| Earnings from Continuing Operations | -15.81 | -8.11 | -9.65 | -6.16 | -15.80 |
| Earnings from Discontinued Operations | -2.25M | -1.81M | -1.12M | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -18.06M | -9.92M | -10.78M | -6.16M | -15.80M |
| EBIT | -15.75M | -18.64M | -20.18M | -20.93M | -15.77M |
| EBITDA | -15.73M | -18.58M | -20.12M | -20.90M | -15.74M |
| EPS Basic | -4.66 | -6.67 | -15.29 | -49.16 | -88.75 |
| Normalized Basic EPS | -4.33 | -7.77 | -13.19 | -35.31 | -54.33 |
| EPS Diluted | -7.40 | -9.41 | -18.03 | -51.90 | -88.75 |
| Normalized Diluted EPS | -1.44 | -4.88 | -10.29 | -32.42 | -54.33 |
| Average Basic Shares Outstanding | 12.04M | 9.39M | 5.22M | 3.03M | 1.39M |
| Average Diluted Shares Outstanding | 24.79M | 22.14M | 17.96M | 15.78M | 1.39M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |